检索结果-南通市图书馆

Serum proteins in chronic hepatitis b patients treated with peginterferon alfa-2b

World Journal of Gastroenterology 2013年第31期19卷 5067-5075页

作者： Sunida Kuakarn Poorichaya SomParn Pisit Tangkijvanich Varocha Mahachai Visith Thongboonkerd Nattiya Hirankarn Medical Microbiology Interdisciplinary Program Graduate School Chulalongkorn University Bangkok 10330 Thailand Immunology Unit Department of Microbiology Faculty of Medicine Chulalong-korn University Bangkok 10330 Thailand Department of biochemistry Faculty of Medicine Chulalongkorn University Bangkok 10330 Thailand Department of Medicine Faculty of Medicine Chulalongkorn University Bangkok 10330 Thailand Medical Proteomics Unit Office for Research and Development Faculty of Medicine Siriraj HospitalMahidol University Bangkok 10700 Thailand Center for Research in Complex Systems Science Mahidol University Bangkok 10700 Thailand

AIM: To study the differential protein profile in serum of hepatitis b ***: Serum samples were obtained from patients with chronic hepatitis b who were receiving peginterferon *** serum samples were subjected to albumin depletion and analyzed by two-dimensional gel electrophoresis(2-DE).Differentially expressed protein spots were identified by electrospray ionizationquadrupole time-of-flight mass ***2-HS-glycoprotein,complement component C3c and CD5 antigen were further analyzed by an enzymelinked immunosorbent assay and ***: Nineteen patients with HbeAg-positive chronic hepatitis b(CHb) were *** patients were followed for at least 1 year after treatment and were classified according to their treatment response: responders(n = 9) and non-responders(n = 10).2-DE and MS/MS analysis were performed to compare the serum proteins before initiating peginterferon *** the quantitative analysis of the 2-D gel,7 proteins were detected between the two groups at different levels before *** these potential candidates,serum levels of alpha-2-HS-glycoprotein,complement component C3c and CD5 antigen-like precursor were further *** the validation phase,23 subjects,9 sustained responders and 14 nonresponders,were ***,the levels of alpha-2-HS-glycoprotein and complement component C3c were elevated in the serum of the non-responders compared to the ***: Serum alpha-2-HS-glycoprotein and complement component C3c may be potential serum biomarkers in predicting the treatment response of peginterferon alfa-2b in patients with CHb prior to treatment.

关键词： Proteomics Peginterferon alfa-2b Chronic hepatitis b Alpha-2-HS-glycoprotein Serum

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C

引用

World Journal of Hepatology 2014年第7期6卷 520-526页

作者： PN Rao Abraham Koshy Jacob Philip Narayanan Premaletha Joy Varghese Krishnasamy Narayanasamy Samir Mohindra Nitin Vikas Pai Manoj Kumar Agarwal Ashokna Konar Hasmukh b Vora Department of Gastroenterology Asian Institute of Gastroenterology Hyderabad 500082 India Department of Hepatology Lakeshore Hospital Kochi 682040 India Department of Gastroenterology Cosmopolitan Hospital Thiruvananthapuram 695004 India Department of Gastroenterology Medical College Thiruvananthapuram 695011 India Department of Hepatology Global Hospitals and Health City Chennai 600100 India Department of Hepatology GGHand MMC Chennai 600003 India Department of Gastroenterology SGPGIMS Lucknow 226014 India Department of Gastroenterology Pai Clinic and Diagnostic Center Pune 411005 India Department of Gastroenterology Belle Vue Clinic Kolkata 700017 India Department of Gastroenterology PeerlessHospital and B.K. Roy Research Center Kolkata 700094 India Department of Gastroenterology Alka Hospital Ahmedabad 380019 India

AIM: To study the safety and efficacy of pegylated interferon alfa-2b, indigenously developed in India, plus ribavirin in treatment of hepatitis C virus(HCV). METHODS: One-hundred HCV patients were enrolled in an open-label, multicenter trial. Patients were treated with pegylated interferon alfa-2b 1.5 μg/kg per week subcutaneously plus oral ribavirin 800 mg/d for patients with genotypes 2 and 3 for 24 wk. The same dose of peginterferon plus weight-based ribavirin(800 mg/d for ≤ 65 kg; 1000 mg/d for > 65-85 kg; 1200 mg/d for > 85-105 kg; 1400 mg/d for > 105 kg body weight) was administered for 48 wk for patients with genotypes 1 and 4. Serological and biochemical responses of patients were ***: Eighty-two patients(35 in genotypes 1 and 4 and 47 in 2 and 3), completed the study. In genotype 1, 25.9% of patients achieved rapid virologic response(RVR): while the figures were 74.1% for early virologic response(EVR) and 44.4% for sustained virologic response(SVR). For genotypes 2 and 3, all patients bar one belonged to genotype 3, and of those, 71.4%, 87.5%, and 64.3% achieved RVR, EVR, and SVR, respectively. In genotype 4, 58.8%, 88.2%, and 52.9% of patients achieved RVR, EVR, and SVR, respectively. The majority of patients attained normal levels of alanine aminotransferase by 4-12 wk of therapy. Most patients showed a good tolerance for the treatment, although mild-to-moderate adverse events were exhibited; only two patients discontinued the study medication due to serious adverse events(SAEs). Eleven SAEs were observed in nine patients; however, only four SAEs were related to study ***: Peginterferon alfa-2b, which was developed in India, in combination with ribavirin, is a safe and effective drug in the treatment of HCV.

关键词： Hepatitis C virus Genotype Peginterferon alfa-2b Ribavirin Treatment

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

干扰素alfa-2b维持治疗对多发性骨髓瘤平顶期的影响:随机研究

引用

国际输血及血液学杂志 1996年第3期 184-185页

作者：佘妙容

用马法兰和其他烷化剂抑制细胞生长治疗多发性骨髓瘤(MM)病人多数可以改善疼痛和其他症状,控制疾病进展,延长生存期。然而,经过30年使用不同烷化剂联合化疗后,MM的中位生存期仍然不超过36～48个月。早期研究显示,alfa干扰素对MM有良好... 详细信息

用马法兰和其他烷化剂抑制细胞生长治疗多发性骨髓瘤(MM)病人多数可以改善疼痛和其他症状,控制疾病进展,延长生存期。然而,经过30年使用不同烷化剂联合化疗后,MM的中位生存期仍然不超过36～48个月。早期研究显示,alfa干扰素对MM有良好的作用。干扰素对肿瘤负荷小及/或增生活性低的肿瘤患者,其疗效比晚期病例和高度恶性的病人好。如果这亦适用手MM,干扰素治疗MM的最佳效果可能是在对诱导治疗发生反应后和疾病的平顶期(Plateau Phase)。本研究评价了标准马法兰-强的松(MP)治疗有效后的MM病人是否可能通过持续的低剂量干扰

关键词：干扰素 MM 抗病毒药维持治疗马法兰 alfa-2b

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

alfa-2b干扰素辅助治疗高危黑色素瘤的疗效及护理

引用

国际护理学杂志 1999年第2期 38-39页

作者：刘箴林秀艳

在美国１９９８年约４１６００名新病例确诊为恶性黑色素瘤，目前该病是美国男性第６位最流行的癌症，是女性第７位最流行癌症。自１９７３年以来黑色素瘤的发病率每年增长４％，到２０００年为止估计每７５位美国人中就有１人患黑色素... 详细信息

在美国１９９８年约４１６００名新病例确诊为恶性黑色素瘤，目前该病是美国男性第６位最流行的癌症，是女性第７位最流行癌症。自１９７３年以来黑色素瘤的发病率每年增长４％，到２０００年为止估计每７５位美国人中就有１人患黑色素瘤。Ａｌｆａ－２ｂ干扰素单独使用或...

关键词：黑色素瘤患者黑色素肿瘤干扰素抗病毒药 alfa-2b 辅助治疗

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：